Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AADI Aadi Bioscience	$1.65	$1.86	$1.21 ▼ $3.81	$40.75M	0.68	261,100 shs	48,668 shs
CYBN Cybin	$7.15 +3.3%	$7.68	$4.81 ▼ $13.88	$168.67M	0.68	320,405 shs	592,928 shs
LYEL Lyell Immunopharma	$10.76 +1.0%	$10.28	$7.65 ▼ $32.40	$204.60M	-0.19	69,615 shs	21,762 shs
MEIP MEI Pharma	$4.97 +7.6%	$4.06	$1.46 ▼ $9.00	$149.54M	0.37	578,303 shs	507,341 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AADI Aadi Bioscience	0.00%	+1.85%	-10.81%	-6.25%	+6.45%
CYBN Cybin	+3.32%	+1.27%	-7.86%	-4.28%	+1,837.67%
LYEL Lyell Immunopharma	+1.03%	+1.70%	-2.09%	+28.68%	-63.15%
MEIP MEI Pharma	+7.58%	+1.64%	-19.84%	+130.63%	+58.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AADI Aadi Bioscience	0.4611 of 5 stars	1.0	0.0	0.0	0.0	2.5	1.3
CYBN Cybin	2.482 of 5 stars	3.6	0.0	0.0	1.7	0.8	1.3
LYEL Lyell Immunopharma	3.7625 of 5 stars	2.8	5.0	0.0	3.0	4.2	1.3
MEIP MEI Pharma	1.5017 of 5 stars	0.0	2.0	4.2	3.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AADI Aadi Bioscience	2.00	Hold	$1.75	6.06% Upside
CYBN Cybin	3.25	Buy	$85.00	1,088.81% Upside
LYEL Lyell Immunopharma	1.50	Reduce	$15.00	39.41% Upside
MEIP MEI Pharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AADI, CYBN, LYEL, and MEIP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/8/2025	CYBN Cybin	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$73.00 ➝ $70.00
6/24/2025	LYEL Lyell Immunopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AADI Aadi Bioscience	$25.07M	1.63	N/A	N/A	$4.29 per share	0.38
CYBN Cybin	N/A	N/A	N/A	N/A	$10.83 per share	N/A
LYEL Lyell Immunopharma	$60K	3,444.99	N/A	N/A	$15.56 per share	0.69
MEIP MEI Pharma	$65.30M	2.46	$6.45 per share	0.77	$4.96 per share	1.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AADI Aadi Bioscience	-$65.76M	-$2.35	N/A	N/A	N/A	-246.06%	-71.87%	-57.28%	11/4/2025 (Estimated)
CYBN Cybin	-$57.88M	-$4.60	N/A	N/A	N/A	N/A	-37.58%	-36.59%	N/A
LYEL Lyell Immunopharma	-$342.99M	-$24.29	N/A	N/A	N/A	-552,328.31%	-85.58%	-68.85%	11/6/2025 (Estimated)
MEIP MEI Pharma	$17.78M	-$4.75	N/A	N/A	N/A	N/A	-77.00%	-64.79%	9/18/2025 (Estimated)

Latest AADI, CYBN, LYEL, and MEIP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	LYEL Lyell Immunopharma	-$3.80	-$2.89	+$0.91	-$2.89	$0.00 million	$0.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AADI Aadi Bioscience	N/A	N/A	N/A	N/A	N/A
CYBN Cybin	N/A	N/A	N/A	N/A	N/A
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A
MEIP MEI Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AADI Aadi Bioscience	N/A	4.89	4.54
CYBN Cybin	N/A	24.24	24.24
LYEL Lyell Immunopharma	N/A	7.65	7.65
MEIP MEI Pharma	N/A	16.78	16.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AADI Aadi Bioscience	52.08%
CYBN Cybin	17.94%
LYEL Lyell Immunopharma	66.05%
MEIP MEI Pharma	52.38%

Insider Ownership

Company	Insider Ownership
AADI Aadi Bioscience	37.30%
CYBN Cybin	15.00%
LYEL Lyell Immunopharma	22.30%
MEIP MEI Pharma	3.12%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AADI Aadi Bioscience	40	24.70 million	15.49 million	Optionable
CYBN Cybin	50	23.59 million	17.96 million	Not Optionable
LYEL Lyell Immunopharma	270	19.21 million	14.93 million	Optionable
MEIP MEI Pharma	100	32.37 million	31.36 million	Optionable

AADI, CYBN, LYEL, and MEIP Headlines

Recent News About These Companies

MEI Pharma (NASDAQ:MEIP) Upgraded at Wall Street Zen

1 hour ago | americanbankingnews.com

MEI Pharma, Inc. (NASDAQ:MEIP) Short Interest Up 12,046.9% in July

August 16, 2025 | marketbeat.com

Short Interest in MEI Pharma, Inc. (NASDAQ:MEIP) Expands By 12,046.9%

August 16, 2025 | americanbankingnews.com

MEI Pharma Welcomes New Board Member Joshua Riezman

August 11, 2025 | theglobeandmail.com

MEI Pharma files to sell 25.3M shares of common stock for holders

August 7, 2025 | msn.com

MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising

August 5, 2025 | joplinglobe.comJ

MEI Pharma’s Strategic Shift with Litecoin Treasury

July 25, 2025 | theglobeandmail.com

MEI Pharma's Bold Bet: First Public Company to Go All-In on Litecoin Treasury

July 25, 2025 | econotimes.com

Public Shell Firms Ramping Up Altcoin Buys Draws Skepticism: FT

July 25, 2025 | coindesk.com

BTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with "capital + technology" dual-driven mode

July 24, 2025 | thenewswire.comT

MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

July 22, 2025 | businesswire.com

MEI Pharma (MEIP) Becomes the First and Only Publicly Traded LTC Holder on a National Exchange

July 20, 2025 | msn.com

MEI Pharma Unveils $100M Litecoin Treasury Plan

July 19, 2025 | livebitcoinnews.comL

GSR leads $100M private placement into Nasdaq-listed MEI Pharma to launch Litecoin treasury

July 18, 2025 | coinjournal.net

MEI Pharma Shares Surge After Unveiling $100 Million Litecoin Treasury Plan

July 18, 2025 | msn.com

MEI Pharma Stock Surges on $100M Private Placement, Litecoin Treasury Strategy

July 18, 2025 | marketwatch.com

MEI Pharma Commits $100M to Litecoin Treasury Strategy: Can LTC Price 10x?

July 18, 2025 | blockonomi.com

Nasdaq-listed MEI Pharma launches $100M Litecoin treasury plan, stock rockets 50%

July 18, 2025 | cryptobriefing.comC

Litecoin Price Forecast: LTC reclaims $100 as NASDAQ-listed MEI Pharma unveils $100 million treasury

July 18, 2025 | fxstreet.com

Big Pharma joins crypto with a private placement for $100 Million Litecoin Treasury Strategy

July 18, 2025 | msn.com

MEI Pharma Announces $100M Placement To Initiate Litecoin Treasury Strategy: Retail Cheers Charlie Lee’s Addition To Company Board

July 18, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI, CYBN, LYEL, and MEIP Company Descriptions

Aadi Bioscience NASDAQ:AADI

$1.65 0.00 (0.00%)

As of 08/21/2025

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Cybin NYSE:CYBN

$7.15 +0.23 (+3.32%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.16 +0.01 (+0.21%)

As of 08/22/2025 07:57 PM Eastern

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

Lyell Immunopharma NASDAQ:LYEL

$10.76 +0.11 (+1.03%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$10.70 -0.06 (-0.60%)

As of 08/22/2025 04:10 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

MEI Pharma NASDAQ:MEIP

$4.97 +0.35 (+7.58%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.00 +0.03 (+0.50%)

As of 08/22/2025 07:54 PM Eastern

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time